Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc(CO)3-NOTA-PEG2Nle-CycMSHhex
- Development stage
- Unknown
- Lead developer
- University of Arizona
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
**99mTc(CO)3-NOTA-PEG2Nle-CycMSHhex** is a radiolabeled peptide-based diagnostic agent developed for SPECT imaging of melanoma. It consists of a lactam-cyclized alpha-melanocyte-stimulating hormone (α-MSH) analog (CycMSHhex) modified with a tricarbonyl technetium-99m core via a NOTA chelator and a PEG2Nle linker. The conjugate exhibits high affinity and specificity for the melanocortin-1 receptor (MC1R), which is overexpressed in melanoma cells. Its mechanism involves specific binding to MC1R on tumor cells, enabling sensitive visualization of melanoma lesions with clear tumor-to-background ratios. The agent displays rapid blood clearance, predominantly renal elimination, and favorable biodistribution with low kidney uptake, making it well-suited for diagnostic nuclear imaging of MC1R-positive melanoma lesions[1].
- Other names
- 99mTc(CO)3-NOTA-PEG2Nle-CycMSHhex99mTc(CO)3-NOTA-GGNle-CycMSHhex99mTc(CO)3-NOTA-conjugated lactam-cyclized alpha-MSH peptide
02
Targets
MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on 99mTc(CO)3-NOTA-PEG2Nle-CycMSHhex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc(CO)3-NOTA-PEG2Nle-CycMSHhex.